MedPath

A Rheumatoid Arthritis study in patients

Phase 3
Conditions
Health Condition 1: null- Rheumatoid Arthritis
Registration Number
CTRI/2012/02/002423
Lead Sponsor
Eli Lilly and Company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Other
Sex
Not specified
Target Recruitment
1505
Inclusion Criteria

Completion of 24 weeks of participation in Study H9B-MC-BCDO or Study H9B-MC-BCDV, or have completed 100 weeks of participation in Study H9B-MC-BCDM

-Woman must not be pregnant, breastfeeding, or become pregnant during the study

Exclusion Criteria

-Current symptoms of a serious disorder or illness

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath